Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:Wel now we know why the madethe deal!

[BeenHereBefore]

Smoke and mirrors.

The ONLY news that matters for Antibe right now is the mandatory Validation Studies results.

Positive results = Phase 2 human trials.
Negative results = The bottom falls out.

LAMBO wrote: Antibe Therapeutics Lead Drug Shows Promising Effects in Alveolar Bone Loss Study These results open up potential uses of Antibes drug candidates in the fields of regenerative medicine, orthopaedic and craniomaxillofacial surgery Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce promising results from an independent bone loss study. A study directed by Dr. Marcelo Muscara at the University of Sao Paulo in Brazil provides compelling evidence that ATB-346, Antibes lead drug candidate for treating chronic inflammatory conditions such as osteoarthritis, has a superior safety profile as compared to conventional non-steroidal anti-inflammatory drugs (NSAIDs) in periodontal disease. NSAIDs, such as naproxen (Aleve), have well characterized adverse effects on bone growth. In the rat study performed by Dr. Muscaras team, induction of periodontitis, an inflammation of the gums, was associated with a marked loss of alveolar bone, which is the thickened ridge of bone that contains the tooth sockets. When the rats were treated with ATB-346 for a week, there was a substantial improvement in the preservation of alveolar bone, while naproxen treatment made the bone loss worse. These results open up potential uses of Antibes drug candidates in the fields of regenerative medicine, orthopaedic and craniomaxillofacial surgery, where the adverse effects of NSAIDs on bone growth are an increasing concern. Antibes CEO, Dan Legault commented, The discovery by Dr. Muscaras team of significant beneficial effects of ATB-346 in prevention of alveolar bone loss adds to our excitement about the strongly differentiated profile of our drug candidates, including the enhanced safety and tolerability that is imparted by the release of hydrogen sulfide from all of our drug development candidates. This discovery, together with our recent acquisition of Citagenix Inc., has Antibe poised to make significant contributions to the development of medications pertinent to regenerative medicine. As observed previously, treatment with naproxen also resulted in significant ulceration and bleeding in the stomach of the rats, while no damage was observed in rats treated with ATB-346. Dr. Muscara commented: The hydrogen sulfide-releasing property of ATB-346 not only prevents tissue injury and bleeding in the stomach, it also markedly improves bone quality, suggesting that it may be a valuable new adjuvant therapy for periodontal disease. The results of this study have been published in the journal Medical Gas Research (https://www.ncbi.nlm.nih.gov/pubmed/25755876).